Narendranath Epperla is an expert in Hematology at James Cancer Hospital (United States). As of October 2026, ScienceLeadR ranks Narendranath Epperla in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Narendranath Epperla has authored 381 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 8 of them ongoing. SLR score: 1,793 (community average: 125). How the SLR is computed.

LeadR Profile

Narendranath Epperla James Cancer Hospital United States
1 793 ScienceLeadR Reputation 1793
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2013 - 2026

Source: PubMed

The Ohio State University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 381

Citations

Citations: 2 711 1st author: 102 Last author: 72 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.
PMID 42893203 — lymphoma
Blood Neoplasia20260
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras.
PMID 42869895 — cells, lymphoma, lymphoma, mantle-cell, therapeutics
Blood Cancer J20260
Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
PMID 42845039 — hematology, hodgkin disease, lymphoma, neutropenia, doxorubicin, dacarbazine, nivolumab, vinblastine, therapeutics
Haematologica20260
A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
PMID 42824791 — cells, progression-free survival, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, immunotherapy, physicians, lenalidomide, therapeutics, b-lymphocytes
EJHaem20262
Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.
PMID 42742125 — cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, neoplasms, immunotherapy, therapeutics, b-lymphocytes
Oncologist20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 9

By phase:

Phase 2 6
Phase 1 4
Phase 1/Phase 2 2

By status:

Recruiting 4
Active not recruiting 2
Not yet recruiting 2
Withdrawn 2
Completed 1
Terminated 1

By type:

Interventional 12

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 5
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Loncastuximab Tesirine and Rituximab as First line Therapy in Patients With Post transplant Lymphoproliferative Disorder (PLUTO)
NCT07573436 — pharmaceutical preparations, rituximab, transplants, therapeutics, lymphoproliferative disorders, biosimilar pharmaceuticals
Phase 1/Phase 2Not yet recruiting2026
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
NCT07548450 — waldenstrom macroglobulinemia
Phase 2Not yet recruiting2026
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard of care CAR T Therapy in Patients With Large B cell Lymphoma (CORAL)
NCT06788964 — cells, lymphoma, b-cell, lymphoma, rituximab, therapeutics, t-lymphocytes, b-lymphocytes, receptors, antigen, t-cell, car-t cell
Phase 2Recruiting2025
Tazemetostat in Combination With Zanubrutinib and Anti CD20 Monoclonal Antibody in Relapsed or Refractory B cell Non Hodgkin Lymphoma
NCT06824701 — cells, hodgkin disease, lymphoma, b-cell, lymphoma, rituximab, antibodies, monoclonal, lymphoma, non-hodgkin, therapeutics, b-lymphocytes, biosimilar pharmaceuticals
Phase 1Active not recruiting2025
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
NCT06607549 — radiosurgery, lymphoma, brain, central nervous system, rituximab, nervous system
Phase 1Recruiting2025

LeadR Networks

Main global connection map